Phase I study of AZD9592 in solid tumors
Phase 1
Recruiting
- Conditions
- Recurrent or metastatic Head and NeckSquamous Cell Carcinoma of the oral cavity,oropharynx, hypopharynx or larynx, Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Metastatic Colorectal CancerMedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10001160Term: Adenocarcinoma lung Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10052358Term: Colorectal cancer metastatic Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10060121Term: Squamous cell carcinoma of head and neck Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10029514Term: Non-small cell lung cancer NOS Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10041826Term: Squamous cell carcinoma of lung Class: 100000004864Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-501570-18-00
- Lead Sponsor
- Astrazeneca AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 626
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does AZD9592 target in head and neck squamous cell carcinoma and non-small cell lung cancer?
How does AZD9592 compare to standard-of-care treatments for metastatic colorectal cancer in early-phase trials?
Which biomarkers are being evaluated for patient selection in the AZD9592 Phase I trial for solid tumors?
What are the potential adverse events associated with AZD9592 in patients with recurrent or metastatic cancers?
Are there combination therapies being explored with AZD9592 for non-squamous non-small cell lung cancer and adenocarcinoma?